AI Moves Beyond Drug Discovery as Clinical Trials Become the Next Critical Arena

The most expensive and failure-prone part of new drug development is often not a flash of insight in the laboratory, but the long and complex clinical trial process after a drug enters the human body. According to a report by Maeil Business Newspaper, artificial intelligence is rapidly spreading from early-stage drug discovery into more stages of the clinical trial process, showing that AI’s role in the biomedical industry is shifting from “finding drugs” to “helping prove whether drugs are effective and safe.”

This shift is not merely an expansion of the technology landscape. Clinical trials involve participant screening, trial site management, tracking efficacy endpoints, identifying adverse events, and organizing vast amounts of data. Each step can affect whether a study is completed on time and can also influence whether the results are credible. If AI can assist with tasks such as matching medical record data, interpreting imaging or laboratory data, and organizing remote monitoring signals, it could in theory reduce the burden of manual work and make trial design more closely reflect real patient populations.

However, the publicly available information on this news is currently quite limited, and no specific company, trial name, disease area, dataset size, or validation results have yet been provided. A more cautious interpretation, therefore, is that it reflects an industry trend that is rapidly taking shape, rather than a single proven breakthrough that can change clinical outcomes. For clinical medicine, whether an AI tool is useful cannot be judged only by the accuracy claimed by the model; it also depends on whether it remains stable across multiple centers, different populations, and real clinical workflows.

The most concrete value of AI applications in clinical trials may appear in “finding the right people” and “detecting problems early.” For example, a system can help compare electronic medical records with inclusion and exclusion criteria to identify patients who may be eligible; it can also flag abnormal signals in continuous monitoring data, images, or laboratory values, prompting the research team to confirm them further. But for these functions to enter formal trial processes, the data sources, model update methods, bias risks, and responsibilities for human review must be clearly explained.

Regulatory issues therefore become sharper as well. The core purpose of clinical trials is not to make processes faster, but to make evidence more reliable. If AI is involved in participant selection, endpoint interpretation, or safety monitoring, researchers need to be able to reconstruct the basis for its judgment at a specific point in time. If a model is difficult to explain like a black box, or performs inconsistently across different hospital information systems, efficiency gains may be offset by compliance risks.

**Background Context**

In recent years, the focus of AI-driven drug development has often been on molecule generation, protein structure prediction, and candidate drug screening. But the industry is gradually realizing that the truly expensive bottleneck often lies in clinical development. From auditable AI drug discovery workflows to trial design, outsourced execution, and regulatory communication, competition in biomedical AI is shifting from demonstrating model capabilities to whether those models can be embedded into regulated R&D chains.

Therefore, AI’s entry into clinical trials does not mean that human research can be replaced by automation. The more likely near-term picture is that AI becomes an auxiliary layer for research teams: accelerating data organization, flagging potential risks, improving recruitment efficiency, and preserving records of decisions that were previously scattered. Whether it can truly shorten the path to new drug approval will still depend on rigorous validation, transparent governance, and whether regulators accept evidence generated or organized with the assistance of these tools.